drugset / Trial / NCT06703398
A Study of GC101 TIL in Advanced Melanoma
RandomizedParallel-groupOpen-labelTreatment
Summary
98 participants will be randomly assigned 1:1 to the experimental group and the control group for the Phase II clinical trial，this trail is expected to be finished in 24 months
Timeline
- Start
- 2024-12-20
- Primary completion
- 2026-07-10
- Completion
- 2026-12-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Cisplatin | Other / unclassified | — | — |
| Comparator | Dacarbazine | Small molecule | — | — |
| Subject | GC101 TIL | Cell therapy | — | Intravenous |
| Comparator | Paclitaxel | Small molecule | — | — |
| Comparator | Temozolomide | Small molecule | — | — |